Meeting Register Page

PTC Therapeutics: 'PTC518' Phase 2 Clinical Trial updates
PTC is developing a potential treatment for Huntington’s disease, based on the PTC splicing platform technology. PTC518, a small molecule that can be taken orally, reduces the production of the mutated huntingtin protein that leads to injury and death of the neuron, which results in disease progression.
Loading
* Required information